The one-step synthesis of [ C]potassium cyanate from [ C]urea is described with product characterization by gravimetric specific activity as well as a novel TLC system. The storage, stability, and repurification of [ C]potassium cyanate are also discussed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jlcr.3829 | DOI Listing |
J Labelled Comp Radiopharm
May 2020
PerkinElmer Health Sciences Inc, Waltham, MA, USA.
The one-step synthesis of [ C]potassium cyanate from [ C]urea is described with product characterization by gravimetric specific activity as well as a novel TLC system. The storage, stability, and repurification of [ C]potassium cyanate are also discussed.
View Article and Find Full Text PDFNucl Med Biol
June 2015
AstraZeneca Translational Science Centre at Karolinska Institutet, Stockholm, Sweden; Karolinska Institutet, Department of Clinical Neuroscience, Center for Psychiatric Research and Education, Stockholm, Sweden.
Introduction: The myeloperoxidase inhibitor AZD3241 has been selected as a candidate drug currently being developed to delay progression in patients with neurodegenerative brain disorders. Part of the decision tree for translation of AZD3241 into clinical studies included the need for assessment of brain exposure in non-human primates by PET microdosing. For that purpose a rapid multistep method for (11)C-labeling of AZD3241 was developed.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!